S1Tx is a preclinical stage biotechnology company developing cannabis-based medicines for FDA-approval in the treatment of pain and central nervous system disorders. Funded in part by the Migraine Research Foundation and the National Institute on Drug Abuse, we were one of the 1st federal recipients of U.S. government small business grants for the development of a THC / cannabis medicine for FDA-approval. Our research is ongoing with partners at the University of Iowa, Leiden University in the Netherlands, and others.